FREEDOM2-DM1

• Research type

  Research Study

• Full title

  A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (FREEDOM2-DM1)

• IRAS ID

  1010096

• Contact name

  Hayley Parker

• Contact email

  clinreg@pepgen.com

• Sponsor organisation

  PepGen Inc.

• Clinicaltrials.gov Identifier

  NCT06667453

• Research summary

  The purpose of this study is to learn about the effects of an “investigational” medicine, PGN-EDODM1, and to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  24/SC/0193

• Date of REC Opinion

  12 Jul 2024

• REC opinion

  Further Information Favourable Opinion